Política de cookies

Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso.

Más información
Solicitud de permisos - Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2016

© Thomson Reuters, Journal Citation Reports, 2016

Indexada en:

Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, Medes, Science Citation Index Expanded.


  • Factor de Impacto: 1,042 (2016)
  • CiteScore 2017: 0,54
    Leer más
  • SCImago Journal Rank (SJR):0,288
  • Source Normalized Impact per Paper (SNIP):0,533

© Thomson Reuters, Journal Citation Reports, 2017

Aten Primaria 2018;50:200-1 - DOI: 10.1016/j.aprim.2017.09.008
Letter to the Editor
Respuesta de los autores
Author's reply
Carles Llor
Via Roma Primary Health Centre, Barcelona, Spain
Dear Editor,

Although unrelated to the main paper, this letter addresses an important topic: how monitoring of antibiotic consumption should be carried out and what measurement systems a country should provide when submitting the antibiotic consumption data. I agree that two different indicators should always be calculated: the defined daily dose (DDD) per 1000 inhabitants per day (DID, DHD in Spanish) and the number of packages per 1000 inhabitants per day (PID, EMHD in Spanish). There are some reasons for considering both types of data. Bruyndockx et al. found that the latter indicator was more clearly associated with the proportion of pneumococcal-non-susceptible strains isolated than DID.1 In some countries, including Spain, DID and PID are increasingly differing which is mainly explained by the increasing numbers of DDDs per package, driven by increasing doses per unit of the two penicillin antibiotics (amoxicillin and co-amoxiclav) and bigger pack sizes (30 pills instead of the classic 24 pills). When it comes to beta-lactams, PID is not increasing at the European level but, conversely, DID is.2 Therefore, having information about both DID and PID better monitors the trend of antibiotic consumption along the years.

This letter considers monitoring the antibiotic consumption with the use of only reimbursement data by the social security system as suggested by the Agencia Española del Medicamento y Productos Sanitarios. However, reimbursement data only gives partial information of the actual consumption. Campos et al. found that the disparity found between reimbursement data by the social security system and sales data was approximately 30% in 2002, 2004 and 2005.3 This difference between the two indicators is mainly explained by the over-the-counter sales of antibiotics, private health insurance (mainly in dentistry), pet veterinary prescriptions and other non-reimbursed courses. If we consider the latest consumption data published in 2016, antibiotic consumption in Spain was close to the average for European countries, a bit more than 22 DID, but it only provided reimbursement data.4 According to the Agencia Española del Medicamento y Productos Sanitarios, the overall antibiotic consumption in 2016 was approximately 33 DID, of which 11-one third-corresponded to non-reimbursed sales (unpublished data). It means that Spain would be in the top five antibiotic consumers among European countries. Portugal and Spain are the only countries providing reimbursement data whereas the rest of the European countries provide sales data, making the comparison across countries misleading.

Antimicrobial resistance is a major health problem that is mainly caused by antibiotic consumption as a whole and does not distinguish from reimbursement data and other non-reimbursed data. Reimbursement data are clearly different from sales data in Spain and, since these data are not always available we clearly advocate that the Iberian countries could accordingly change the data given and monitor the trend of antibiotic consumption with the utilisation of the whole antibiotic consumption data instead.

Conflicts of interest

I report receiving research grants from the European Commission (Sixth & Seventh Programme Frameworks and Horizon 2020), Catalan Society of Family Medicine, Instituto de Salud Carlos III and Alere.

R. Bruyndonckx,N. Hens,M. Aerts,H. Goossens,J. Cortiñas Abrahantes,S. Coenen
Exploring the association between resistance and outpatient antibiotic use expressed as DDDs or packages
J Antimicrob Chemother, 70 (2015), pp. 1241-1244 http://dx.doi.org/10.1093/jac/dku525
R. Bruyndonckx,N. Hens,M. Aerts,H. Goossens,G. Molenberghs,S. Coenen
Measuring trends of outpatient antibiotic use in Europe: jointly modelling longitudinal data in defined daily doses and packages
J Antimicrob Chemother, 69 (2014), pp. 1981-1986 http://dx.doi.org/10.1093/jac/dku063
J. Campos,M. Ferech,E. Lázaro,F. de Abajo,J. Oteo,P. Stephens
Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data
J Antimicrob Chemother, 60 (2007), pp. 698-701 http://dx.doi.org/10.1093/jac/dkm248
European Centre for Disease Prevention and Control
Summary of the latest data on antibiotic consumption in EU
Copyright © 2017. The Author